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The Future – Disruptive Optometry
Change is the only constant. How our profession embraces, and indeed leads, disruption will be the key to our collective successful future. The pace of disruption, both in our world and in our industry, is accelerating, forcing independent optometrists to examine their practices with a view to meeting changing patient needs 
and embracing technology, while also ensuring patient safety. This opportunity allows the profession of optometry 
to get ahead of the curve and lead change, rather than be a victim of it. The Canadian Association of Optometrists 
invited four leaders in the industry to provide their perspectives on disruptive optometry and how optometrists can 
be the disruptor, rather than the disrupted.
In recent years, there have been disruptions in several industries, including urban transportation (ride sharing), travel (vacation rentals) and financial services (online banking), that have enjoyed massive success. As a result, there are increasing numbers of entrepreneurs working tirelessly to create a technology and/or concept that will 
be the next big “game changer” in an established industry. These disrupters usually originate from outside the indus-
try, and for good reason. Being an outsider gives them the objectivity of distance from the limitations of tradition, con-
vention and occasionally legislation, along with the invaluable perspective of the un-biased consumer. These insights 
allow for disruptors to identify gaps within the conventional models of the industry where customers are not currently 
being serviced. The gaps become opportunities to solve problems for the consumer in a new and innovative way.
Optometry, like any other profession, has its gaps, where the consumer is not getting exactly what they want but rather 
is experiencing the status quo. In our view, we need to get ahead of disruptions by regularly ‘disrupting’ ourselves with a 
mindset of openness and continual self-reflection. The challenge is to ask the right questions, no matter how difficult they 
might be, because the questions you ask yourself will shape what your practice will become in the future.
 At IRIS, we asked ourselves what our patients wanted that was missing in our model of eye care. The answer? An 
increasing demand for information, transparency, and a more personalized experience. Using this information as a 
foundation, we pushed ourselves to develop a strategy and tool, using tablet-based technology to enhance the eye 
exam and eyewear sales experience. The tool and the strategy both serve to differentiate our group in the market 
and close the gap with consumers.
After implementation of new tools and technology, it is especially important to measure their impact. In our case we 
use frequent observation, detailed analytic measurement of results, and patient feedback to guide us. The results that you 
measure can help you to ask more questions and make further improvements. This cycle of self-reflection and adjustment 
is critical to success and one that is consistently employed by disruptive entrepreneurs who change our world.
With this knowledge, I firmly believe that if we as individual practitioners, groups and a profession develop a 
habit of continuing to question our own conventions, we may just resist that next big disruption on the horizon.
Dr. Daryan Angle
Vice President Business Development, IRIS, The Visual Group
Why are online companies targeting eye care and the optical business? Why does independent optometry feel under attack from disruptive technology, online refraction, virtual online fitting or remote online diagnostics? The reality is that optometry is no more a target for disruption than the rest of the health 
care system, which has traditionally been slow to adapt to technology and change. The system’s reaction to new 
technology has often been to dismiss it or seek legislative protection. Slow-moving industries or companies are the 
low-hanging fruit for technology disruptors. So how can optometry get ahead of disruptors, embrace technology 
and create sustainable growth in the future?
1. Disruptive technology is good – Many studies have shown that new technology forces businesses to 
innovate and differentiate. The first disruptors in an industry often have not thought of the long-term, 
legal or safety implications of their products or services. Disruptors in optometry have forced many offices 
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to think about how they create a patient 
experience, demonstrate quality, create an 
efficient eye exam process, and even what 
it means to be an eye care professional. 
The future of optometry should be focused 
on serving patients better, rather than on 
government protection from market disruption.
2. Embrace change – Regardless of how secure your 
business is, you can’t prevent disruption. If your 
reaction to disruption is to create differentiated 
value with consumers and patients, you will 
always be able to compete with disruptors. 
Start by incorporating learning as part of your 
organizational culture and provide opportunities 
for your staff and associates to learn and grow. 
Create processes and a structure that encourage 
sharing and learning. Any office or organization 
can develop a learning or disruptive mindset, but 
it needs a champion. Change begins with fearless 
leaders demonstrating the rewards and value of 
change to office staff and patients.
3. Listen to your patients – Patient surveys and 
research consistently show a demonstrated 
preference for comprehensive eye care 
delivered by local optometrists. Some of the 
most disruptive technologies in eye care have 
focused on simplifying the eye care process. 
By making the eye care experience simple, 
comprehensive and personal, optometrists 
can effectively maintain their status as “the” 
primary eye care expert with patients, while 
opening up opportunities in other specialty 
areas. 
An optometrist eye care expert using the latest tech-
nology represents the ultimate disruptor in eye care! 
Grant Larsen
CEO Eye Recommend
Disruption is not a new word for any industry and companies that have been identified as dis-ruptive are often rewarded for it. Amazon is an 
obvious example, but we have also seen this in our in-
dustry with Clearly and Warby Parker. Disruptors take 
a “tired” or “old-fashioned” industry and use technol-
ogy and new delivery models to deliver products and 
services that align with current and future consumer 
expectations.
Technology itself can also be a significant disruptor. 
The best example of this is streaming technology. For 
example, Blockbuster Entertainment, an American-
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Important Safety Information
Indications and clinical use:
Xiidra® is indicated for the treatment of the signs and symptoms 
of dry eye disease.
Contraindications:
Patients who are hypersensitive to this drug or to any 
ingredients in the formulation or component of the container 
should avoid taking Xiidra. For a complete listing, see the 
Dosage Forms, Composition and Packaging section of the 
Product Monograph.
Relevant Warnings and Precautions:
Use in Specific Populations:
Pregnancy: There are no adequate and well-controlled 
studies of Xiidra use in pregnant women. Xiidra should be 
used with caution during pregnancy.
Lactation: It is not known whether Xiidra is excreted in 
human milk. Because many drugs are excreted in human milk, 
caution should be exercised when Xiidra is administered to a 
nursing woman.
Pediatric Use: Safety and efficacy in pediatric patients have 
not been established.
Geriatric Use: No overall differences in safety or effectiveness 
have been observed between elderly and younger patients.
Adverse Reactions:
In clinical trials, the most common ocular adverse reactions were 
eye irritation (18%), eye pain (13%) and instillation site reaction 
(12%); the most common non-ocular adverse reaction was 
dysgeusia (14%). 
Hypersensitivity adverse reactions, including anaphylactic 
reaction/anaphylaxis, type IV hypersensitivity with respiratory 
distress, swollen tongue, and asthma have been reported in 
postmarketing experiences.
Dosage and Administration:
Instill one drop of Xiidra twice daily (approximately 12 hours apart) 
into each eye using a single-use container. Discard the single-use 
container immediately after using in both eyes. Contact lenses 
should be removed prior to the administration of Xiidra and may 
be reinserted 15 minutes following administration.
For more information:
Consult the complete Product Monograph at  
http://www.shirecanada.com/pm/en/Xiidra.pdf for further 
information on contraindications, warnings, precautions, 
adverse reactions, and dosage and administration. The Product 
Monograph is also available at: 1-800-268-2772.
Over 2,400 patients with Dry Eye Disease took part in 5 different clinical trials with Xiidra1,‡
XIIDRA IIMPROVED  
SYMPTOMS OF EYE DRYNESS 
IN AS EARLY AS 2 WEEKS
Clinical trials showed Xiidra® improved eye dryness in 12, 6, and as 
early as 2 weeks vs. vehicle as measured by Eye Dryness Score (EDS).*
‡ Comparative clinical significance has not been established.
Xiidra is the first and  
only molecule in its class.‡ 
Lifitegrast is a lymphocyte 
function-associated antigen-1 
(LFA-1) antagonist.
Indication
Xiidra is indicated for the 
treatment of the signs and 
symptoms of Dry Eye Disease.
Study Design
The efficacy of Xiidra vs. 
vehicle was evaluated in four 
randomized, double-masked, 
12-week trials, enrolling 
patients with a history  
of Dry Eye Disease.
* In 2 of 4 clinical trials, Xiidra improved eye dryness in  
12, 6, and as early as 2 weeks1
 In OPUS-3 (Study 4; N = 711), a significant difference in mean change from baseline to 
Day 84 in EDS favouring Xiidra (−37.7) over vehicle (−30.5) was observed (p = 0.0007). 
Significant improvement in mean change from baseline of EDS was seen in the  
Xiidra group over vehicle for key secondary endpoints at Day 14 (−22.7 vs. −14.9,  
p <0.0001) and Day 42 (−33.0 vs. −23.7, p <0.0001).1,2
In OPUS-2 (Study 3; N = 718), a statistically significant difference in mean change 
from baseline to Day 84 in EDS (co-primary symptoms endpoint) favouring Xiidra 
(−35.30) over vehicle (−22.75) was observed (p <0.0001). A post hoc analysis of mean 
change from baseline in EDS for secondary endpoints showed a treatment effect as 
early as Day 14 for Xiidra over vehicle (−19.7 vs. −13.1) and at Day 42 (−28.3 vs. −18.2).1,3
In OPUS-2, Xiidra treatment did not result in a statistically significant difference for 
the co-primary sign endpoint (ICSS).1,3
Demonstrated Statistically Significant 
Symptom Improvement
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based provider of home movie and video game rentals, declined the opportunity to buy Netflix (reportedly for 
$60M) because corporate executives doubted the future of streaming video. We all know how that ended. In our 
industry, we have new telemedicine platforms, online refraction and dispensing, smartphone auto-refraction, kiosk 
medicine and home delivery eye care which, combined, could have an impact on the way we practice our profession. 
In my opinion, one of the biggest disruptors will be the consolidation of independent clinics. The logic for con-
solidation requires understanding the motivation of those pursuing it. Consolidators possess the financial capacity 
and scalability to create brands that compete with independent doctors. They can build the technology to disrupt 
unlike anything available to an independent doctor. This is not a bad thing, but financially motivated consolidation 
has not been good for optometry in other markets, and it can happen remarkably fast.
What solutions can individual doctors offer to combat all of this potential disruption? We have all heard that the 
combination of a positive patient relationship and excellent customer service will ensure a thriving independent 
optometric practice. I agree that the power of the relationship we have with our patients is critical to a successful 
practice. I would caution however, that consumer expectations are changing. The traditional model of going for an 
eye exam and choosing glasses is not very convenient for the consumer. Practices that create a brand that means 
something to the consumer, offer innovative products, enable technology to improve and deliver a great experience 
will truly thrive and ultimately emerge as the long-term winners in our industry 
Independent doctors will continue to be challenged in their practices, but they can choose to redefine the patient 
experience. Self-disruption using new technologies in refraction, binocular vision testing, and delegation of services 
provides opportunities for doctors to differentiate themselves and re-define the traditional experience. How we 
communicate has also changed, and it is incumbent on us to find a way to communicate with consumers in a man-
ner and with a frequency that is meaningful to them. For example, Beacon technology (targeted marketing using 
geolocation) represents a brand-new frontier in the retail space and an intriguing way of enabling communication 
with patients in the mobile environment. We have all seen the future and it IS mobile! 
We owe it to ourselves to invest in disruption, rather than become victims of it. We need to think differently 
and reflect on how we are perceived by the patient. Optometric leaders need to find ways to embrace, support 
and where possible, provide technological innovation not only to compete with today's disruption, but also the 
inevitable and ongoing change of tomorrow. Disruption in our industry is real and tangible, and doctors should 
approach it as both an opportunity and threat, and should act quickly to incorporate or mitigate disruption in 
their own practices.
Dr. Alan Ulsifer
Chair & CEO, FYI Doctors
We are living in a fast-paced technological world that is challenging all industries, including optometry. Disruptors confront optometrists daily and will continue to do so. There’s a revolution happening out-side the exam room. Now, more than ever, the patient is driving change. The use of tablets, computers, 
smartphones, and ubiquitous net access to information has led patients to adopt new ways of communicating and 
shopping. Patient choice is evolving and clinics need to adapt accordingly to stay relevant and attractive to their 
existing and potential patient base. 
EMBRACE CHANGE WITH THE RIGHT PRACTICE MANAGEMENT SOFTWARE
The ability of a clinic and its staff to adapt to change is positively correlated to a practice’s success. Practices that 
favor the status quo will one day be outmatched by counterparts that choose to adjust to the changing optometric 
landscape.
Technology has revolutionized the way consumers engage with products, services and health professionals. A 
platform like Twitter has even changed how some heads of state communicate! For the optometric industry, to-
day’s empowered patient expects optometrists to understand their needs, their history and their communication 
preferences. And since patients are now doing practically everything using their smartphones, there is a growing 
likelihood that, unless your services are realigned to reflect this new reality, some patients will decide to switch 
optometrists to find the convenience they expect.
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DEALING WITH DISRUPTION
The key is to have a product management software (PMS) that drives evolution in your clinic. Your PMS needs 
to have the ability to make and track communication within the patient file by email or text message to maximize 
engagement. Because your PMS is the central repository of all your patients’ information, it is crucial that all contact 
with your patient reside in their file, which should be easily accessible to their care team. 
Big data helps to improve patient care. Data is knowledge and knowledge is power. The right PMS will allow 
you to track your own key performance indicators (KPIs) to identify trends and opportunities for improvement 
within your practice. Another indispensable tool is the ability to easily issue a patient experience survey that 
allows you to assess your patients’ satisfaction over time. In this way, clinic data analysis becomes a compre-
hensive examination of the health of your practice. You don’t know what you’ll find until you have the right 
tools and expertise to look!
Practice management systems such as Optosys (OSI’s proprietary software) incorporate some specific technolo-
gies that align with the new optometric landscape, including:
• Online appointment booking module: Not all patients have time during your business hours to phone in, 
wait on hold, and negotiate with a live person to book an exam at your convenience. Patients want the 
flexibility to book appointments online, chose the optometrist they wish to see and select the time slots 
that work best for them. With 24/7 access to scheduling, exam booking becomes easier and more attrac-
tive for many patients browsing online or working shifts who you otherwise would struggle to reach.
• Automated Recalling: What once took up an enormous amount of staff time, with varying degrees of 
success, can now be fully automated by the Optosys communication module. By connecting with their 
platform of choice (text or email), Optosys will inform your patients that it’s time to book an eye exam or 
remind them that their exam is coming up, thus minimizing “lates” and “no shows”. 
• Direct-to-Lab eOrders: To improve staff efficiency, electronic lab orders can be sent directly from the 
patient file to the lab. This reduces transcription errors that can negatively impact delivery times and a 
patient’s level of satisfaction with your services.
• eCommerce functionalities: An eBoutique can be created to display inventory online. We know that 
today’s consumers want to view things online before going to a store. This module allows you to tap into 
that consumer demographic and reach new consumers who would not otherwise visit your practice.
OPTIMISM FOR THE FUTURE
For years, you have been urged to have the latest and most advanced equipment in your pre-test and exam room. 
Optometrists now have the opportunity to do the same for all aspects of their clinic’s operations. Independent prac-
tices can remain highly competitive for years to come if they embrace all technologies that can help them improve 
patient care and clinic performance. 
Patrice Lacoste
CEO, Optometric Services Inc. (OSI)
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